Craft

Galera Therapeutics

Stock Price

$0.1

2024-10-29

Market Capitalization

$2.9 M

2024-10-29

Galera Therapeutics Summary

Company Summary

Overview
Galera Therapeutics is a clinical-stage biotech company focused on the development of drugs targeting the oxygen metabolic pathways. The company's lead compounds are small molecule dismutase mimetics which closely mimic the activity of the human superoxide dismutase enzymes.
Type
Public
Status
Active
Founded
2009
HQ
Malvern, PA, US | view all locations
Website
http://galeratx.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • J. Mel Sorensen, President and Chief Executive Officer

    • Robert A. Beardsley

      Robert A. Beardsley, Chief Operating Officer

      • Dennis P. Riley

        Dennis P. Riley, Chief Scientific Officer

        • Jon T. Holmlund

          Jon T. Holmlund, Chief Medical Officer

          Operating MetricsView all

          Diseases Treated

          4

          Oct, 2019

          Patents (Europe)

          7

          Oct, 2019

          Phase I Trials Products

          1

          Oct, 2019

          LocationsView all

          1 location detected

          • Malvern, PA HQ

            United States

            2 W Liberty Blvd #110

          Galera Therapeutics Financials

          Summary Financials

          Net income (FY, 2025)
          $149.0M
          Cash (FY, 2025)
          $6.4M
          EBIT (FY, 2025)
          ($2.5M)

          Footer menu